News

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...
Fierce Pharma2d

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Novo Nordisk shares pop after Wegovy receives U.S. approval for liver disease

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...
MedCity News2d

FDA Approval Expands Novo Nordisk’s Wegovy to the Fatty Liver Disease MASH

Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...
Medscape2d

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

FDA Approves Novo Nordisk’s Wegovy for Liver Disease

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...
BioPharma Dive2d

Novo’s Wegovy becomes first GLP-1 drug approved for MASH

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Novo Advances After US Clears Wegovy for Liver Disease

Novo Nordisk A/S shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a ...